Biogen Idec Grows Revenue 7% in 'High Quality' 1Q Miss
By Marie Powers
Wednesday, May 2, 2012
Biogen Idec Inc. added 1,900 Tysabri (natalizumab) patients during the first three months of 2012, increasing revenues from the multiple sclerosis drug by 14 percent year over year to $286 million, on global in-market sales of $399 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.